Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of EDP-938 in adult hematopoietic cell transplant recipients with severe RSV upper respiratory tract infection
MOH_2020-12-20_009415Phase 2Not yet recruiting
- Sponsor
- Enanta Pharmaceuticals
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Development of lower respiratory tract complication. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2020-12-20_009415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-20_009415.